Akinbami Lara J, Santo Loredana, Williams Sonja, Rechtsteiner Elizabeth A, Strashny Alexander
Natl Health Stat Report. 2019 Sep(128):1-20.
Objective-This report describes asthma visits to offices of nonfederally employed U.S. physicians. Methods-Asthma visits are defined by the first-listed diagnosis from National Ambulatory Medical Care Survey data. Asthma visit rates among the general population and among persons with asthma (at-risk rates) were estimated. Trends from 2001 through 2016 were assessed. Asthma visit characteristics were assessed for the period 2012-2015 (the diagnostic coding system was changed to the International Classification of Diseases, 10th Revision, Clinical Modification in 2016). The consistency of visit characteristics with national asthma guidelines was also assessed. Results-From 2001 through 2016, population-based asthma visit rates declined from 40.2 to 30.7 visits per 1,000 persons, and at-risk visit rates from 55.5 to 36.7 visits per 100 persons with asthma. During 2012-2015, there was an annual average of 10.2 million asthma visits: 63.5% were by non-Hispanic white persons, 53.8% by female patients, and 32.5% by children under age 15 years. Population and at-risk visit rates were similar across sex and racial and ethnic groups. Children aged 0-4 years had the highest at-risk asthma visit rate. Primary care physicians saw 60.0% of asthma visits. Asthma severity was documented in 34.5% of visits, asthma control in 40.9%, spirometry in 14.9%, and peak flow in 3.3%. Asthma education was provided in 21.4% of asthma visits and asthma action plans in 9.9%. Bronchodilators were the most commonly mentioned medication class (24.9%). A quick-acting relief medication was the most frequently mentioned (albuterol, 16.9%), followed by asthma-control medications (montelukast, 4.7%; fluticasone-salmeterol, 3.7%; and prednisone, 2.7%). Conclusions-Asthma physician office visit rates declined from 2001 through 2016. During 2012-2015, primary care providers saw nearly two-thirds of asthma visits. Physician adherence to documenting asthma severity or control and providing patient education appeared low. Quick-acting relief medication was the most frequently prescribed medication.
目的——本报告描述了美国非联邦雇员医生办公室的哮喘就诊情况。方法——哮喘就诊由国家门诊医疗护理调查数据中的首要诊断定义。估算了普通人群和哮喘患者(风险率)中的哮喘就诊率。评估了2001年至2016年的趋势。对2012 - 2015年期间的哮喘就诊特征进行了评估(2016年诊断编码系统变更为《国际疾病分类》第十次修订本临床修订版)。还评估了就诊特征与国家哮喘指南的一致性。结果——2001年至2016年,基于人群的哮喘就诊率从每1000人40.2次降至30.7次,哮喘患者的风险就诊率从每100名哮喘患者55.5次降至36.7次。2012 - 2015年期间,哮喘就诊年均有1020万次:63.5%为非西班牙裔白人,53.8%为女性患者,32.5%为15岁以下儿童。不同性别、种族和族裔群体的人群和风险就诊率相似。0 - 4岁儿童的哮喘风险就诊率最高。初级保健医生诊治了60.0%的哮喘就诊患者。34.5%的就诊记录了哮喘严重程度,40.9%记录了哮喘控制情况,14.9%进行了肺功能测定,3.3%进行了呼气峰值流量测定。21.4%的哮喘就诊提供了哮喘教育,9.9%提供了哮喘行动计划。支气管扩张剂是最常提及的药物类别(24.9%)。速效缓解药物是最常提及的(沙丁胺醇,16.9%),其次是哮喘控制药物(孟鲁司特,4.7%;氟替卡松 - 沙美特罗,3.7%;泼尼松,2.7%)。结论——2001年至2016年哮喘患者到医生办公室就诊率下降。2012 - 2015年期间,初级保健提供者诊治了近三分之二的哮喘就诊患者。医生在记录哮喘严重程度或控制情况以及提供患者教育方面的依从性似乎较低。速效缓解药物是最常开具的药物。